Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 5Completed 5Active not recruiting 5Terminated 3Unknown 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 3Recurrence 2Neoplasms 2Melanoma 2Glioblastoma 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Rectal Neoplasms 1Penile Neoplasms 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Ependymoma 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Squamous Non-Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Nivolumab 6pembrolizumab 3Specimen Handling 3Ipilimumab 3relatlimab 2cemiplimab 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2vedolizumab 1trametinib 1toripalimab 1sulforaphane 1gadopiclenol 1famitinib 1anlotinib 1X-Rays 1Watchful Waiting 1Ultraviolet Therapy 1Toll-Like Receptor 1 1Therapeutics 1Temozolomide 1Technetium 1Standard of Care 1Sentinel Lymph Node Biopsy 1SHR-1701 1Rehabilitation 1Phototherapy 1Photopheresis 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Melanoma × cemiplimab × Clear all
NCT07527325 2026-06-05

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

University of California, Irvine

Phase 2 Not yet recruiting
35 enrolled
Dermatologic

Melanoma

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡